Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Find out more
Revatio
Read More
Revatio (sildenafil), manufactured by Pfizer, is a selective inhibitor of the phosphodiesterase 5 (PDE5) enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Market Spotlight: Axial Spondyloarthritis (axSpA)

$1,318.00

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
September 22, 2022
Find out more
Xeljanz
Read More
While Xeljanz (tofacitinib; Pfizer/Takeda) demonstrated positive efficacy in its Phase III clinical trial

program, its future in psoriasis is uncertain.
October 17, 2017
Find out more
Parkinson’s Disease KOL Interview – Italy

$599.00

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key branded Parkinson’s disease drugs, unmet needs, and promising pipeline candidates and how they compare to one another.
October 10, 2022
Find out more
Market Spotlight: Cervical Cancer

$1,318.00

This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
September 15, 2022
Find out more
Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration (including cell-based therapies and tissue scaffolds and grafts). Geographic markets covered by this analysis include the US, Japan, five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW), which includes all other countries.
October 11, 2019
Find out more
Rydapt
Read More
Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways.
July 6, 2017
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Angioplasty Catheters Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of angioplasty catheters, specifically plain old balloon angioplasty (POBA), drug-coated balloon (DCB), cutting balloon, and scoring balloon catheters, used in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD).
November 28, 2017
Find out more
LR769
Read More
LR769 is a recombinant factor VIIa (rfVIIa) therapy in development by LFB for patients with hemophilia A or B with inhibitors.
May 4, 2018
Find out more
Ipatasertib
Read More
Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt.
February 26, 2020
Find out more
Mirogabalin
Read More
Mirogabalin (Daiichi Sankyo) is an oral therapy that preferentially and selectively binds to the α2δ-1 (alpha-2 delta-1) subunit of calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.
May 31, 2018
Find out more
Volasertib
Read More
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.
April 22, 2014
Find out more
Ensartinib
Read More
Ensartinib is a second-generation ALK inhibitor developed by Xcovery. In approximately 3–5% of all NSCLC patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells (Soda et al., 2008; Solomon et al., 2013).
August 30, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *